|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adoptive immunotherapy for acute leukemia:New insights in chimeric antigen receptors显示文摘Relapses remain a major concern in acute leukemia. It is well known that leukemia stem cells(LSCs) hide in hematopoietic niches and escape to the immune system surveillance through the outgrowth of poorly immunogenic tumor-cell variants and the suppression of the active immune response. Despitethe introduction of new reagents and new therapeutic approaches, no treatment strategies have been able to definitively eradicate LSCs. However, recent adoptive immunotherapy in cancer is expected to revolutionize our way to fight against this disease, by redirecting the immune system in order to eliminate relapse issues. Initially described at the onset of the 90's, chimeric antigen receptors(CARs) are recombinant receptors transferred in various T cell subsets, providing specific antigens binding in a non-major histocompatibility complex restricted manner, and effective on a large variety of human leukocyte antigen-divers cell populations. Once transferred, engineered T cells act like an expanding 'living drug' specifically targeting the tumor-associated antigen, and ensure long-term antitumor memory. Over the last decades, substantial improvements have been made in CARs design. CAR T cells have finally reached the clinical practice and first clinical trials have shown promising results. In acute lymphoblastic leukemia, high rate of complete and prolonged clinical responses have been observed after anti-CD19 CAR T cell therapy, with specific but manageable adverse events. In this review, our goal was to describe CAR structures and functions, and to summarize recent data regarding pre-clinical studies and clinical trials in acute leukemia. | Mael Heiblig Mohamed Elhamri Mauricette Michallet Xavier Thomas | 2015 | World Journal of Stem Cells2015，7，7： | 9 |
| 2 | Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients显示文摘AIM: To determine the prevalence of hepatitis B virus (HBV) in adult human immunodeficiency virus (HIV) patients with CD4+ T-cell count less than 500/mm 3 and without antiretroviral therapy; to describe different HBV-HIV coinfection virological profiles; and to search for factors associated with HBs antigen (HBsAg) presence in these HIV positive patients.METHODS: During four months (June through September 2006), 491 patients were received in four HIV positive monitoring clinical centers in Abidjan. Inclusion criteria: HIV-1 or HIV-1 and 2 positive patients, age ≥ 18 years, CD4+ T-cell count < 500/mL and formal and signed consent of the patient. Realized blood tests included HIV serology, CD4+ T-cell count, quantitative HIV RNA load and HBV serological markers, such as HBsAg and HBc antibody (anti-HBcAb). We performed HBeAg, anti-HBe antibody (anti-HBeAb), anti-HBc IgM and quantitative HBV DNA load in HBsAg positive patients. Anti-HBsAb had been tested in HIV patients with HBsAg negative and anti-HBcAb-positive. HBV DNA was also tested in 188 anti-HBcAb positive patients with HBsAg negative status and without anti-HBsAb. Univariate analysis (Pearsonχ 2 test or Fischer exact test) and multivariate analysis (backward step-wise selection logistic regression) were performed as statistical analysis. RESULTS: Mean age of 491 patients was 36 ± 8.68 years and 73.3% were female. Type-1 HIV was found in 97% and dual-type HIV (type 1 plus type 2) in 3%. World Health Organization (WHO) clinical stage was 1, 2, 3 and 4 respectively in 61 (12.4%), 233 (47.5%), 172 (35%) and 25 patients (5.1%). Median CD4+ T-cell count was 341/mm 3 (interquartile range: 221-470). One hundred and twelve patients had less than 200 CD4+ T-cell/mm 3 . Plasma HIV-1 RNA load was elevated (≥ 5 log 10 copies/mL) in 221 patients (45%). HBsAg and anti-HBcAb prevalence was respectively 13.4% and 72.9%. Of the 66 HBsAg positive patients, 22 were inactive HBV carriers (33.3%), 21 had HBeAg positive hepatitis (31.8%) and 20 had HBeAg negative hepatitis (30.3%). HBeAg and anti-HBeAb were indeterminate in 3 of them. Occult B infection prevalence (HBsAg negative, anti-HBcAb positive, anti-HBsAb negative and detectable HBV DNA) was 21.3%. Three parameters were significantly associated with the presence of HBsAg: male [odds ratio (OR): 2.2;P = 0.005; 95% confidence interval (CI): 1.3-3.8]; WHO stage 4 (OR: 3.2;P = 0.01;95% CI: 1.3-7.9); and aspartate aminotransferase (AST) level higher than the standard (OR: 1.9;P = 0.04; 95% CI: 1.02-3.8). CONCLUSION: HBV infection prevalence is high in HIV-positive patients. HBeAg positive chronic hepatitis and occult HBV infection are more frequent in HIVpositive patients than in HIV negative ones. Parameters associated with HBsAg positivity were male gender, AIDS status and increased AST level. | Koffi Alain Attia Serge Eholié Eugène Messou Christine Danel Sandrine Polneau Henri Chenal Thomas Toni Myreille Mbamy Catherine Seyler Naomi Wakasugi Thérèse N'dri-Yoman Xavier Anglaret | 2012 | World Journal of Hepatology2012，4，7： | 4 |
| 3 | 在尖锐成淋巴细胞的白血病和酷氨酸 kinase 禁止者治疗的费城染色体积极的白血病干细胞显示文摘 Leukemia stem cells(LSCs),which constitute a minority of the tumor bulk,are functionally defined on the basis of their ability to transfer leukemia into an immunodeficient recipient animal.The presence of LSCs has been demonstrated in acute lymphoblastic leukemia(ALL),of which ALL with Philadelphia chromosome-positive(Ph+).The use of imatinib,a tyrosine kinase inhibitor(TKI),as part of front-line treatment and in combination with cytotoxic agents,has greatly improved the proportions of complete response and molecular remission and the overall outcome in adults with newly diagnosed Ph+ ALL.New challenges have emerged with respect to induction of resistance to imatinib via Abelson tyrosine kinase mutations.An important recent addition to the arsenal against Ph+ leukemias in general was the development of novel TKIs,such as nilotinib and dasatinib.However,in vitro experiments have suggested that TKIs have an antiproliferative but not an antiapoptotic or cytotoxic effect on the most primitive ALL stem cells.None of the TKIs in clinical use target the LSC.Second generation TKI dasatinib has been shown to have a more profound effect on the stem cell compartment but the drug was still unable to kill the most primitive LSCs.Allogeneic stem cell transplantation(SCT) remains the only curative treatment available for these patients.Several mechanisms were proposed to explain the resistance of LSCs to TKIs in addition to mutations.Hence,TKIs may be used as a bridge to SCT rather than monotherapy or combination with standard chemotherapy.Better understanding the biology of Ph+ ALL will open new avenues for effective management.In this review,we highlight recent findings relating to the question of LSCs in Ph+ ALL. | Xavier Thomas | 2012 | World Journal of Stem Cells2012，4，6： | 4 |
| 4 | Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study显示文摘 | Michael P. Curry Xavier Forns Raymond T. Chung Norah A. Terrault Robert Brown Jonathan M. Fenkel Fredric Gordon Jacqueline O’Leary Alexander Kuo Thomas Schiano Gregory Everson Eugene Schiff Alex Befeler Edward Gane Sammy Saab John G. McHutchison G. Mani S | 2014 | Gastroenterology2014，，： | 3 |
| 5 | Gastrointestinal B-cell lymphomas:From understanding B-cell physiology to classification and molecular pathology显示文摘The gut is the most common extranodal site where lymphomas arise. Although all histological lymphoma types may develop in the gut, small and large B-cell lymphomas predominate. The sometimes unexpected finding of a lymphoid lesion in an endoscopic biopsy of the gut may challenge both the clinician (who is not always familiar with lymphoma pathogenesis) and the pathologist (who will often be hampered in his/her diagnostic skill by the limited amount of available tissue). Moreover, the past 2 decades have spawned an avalanche of new data that encompasses both the function of the reactive B-cell as well as the pathogenic pathways that lead to its neoplastic counterpart, the B-cell lymphoma. Therefore, this review aims to offer clinicians an overview of B-cell lymphomas in the gut, and their pertinent molecular features that have led to new insights regarding lymphomagenesis. It addresses the question as how to incorporate all presently available information on normal and neoplastic B-cell differentiation, and how this knowledge can be applied in daily clinical practice (e.g., diagnostic tools, prognostic biomarkers or therapeutic targets) to optimalise the managment of this heterogeneous group of neoplasms. | Xavier Sagaert Thomas Tousseyn Rhonda K Yantiss | 2012 | World Journal of Gastrointestinal Oncology2012，4，12： | 2 |
| 6 | Experimental study of pulse-jet cleaning of bag filters supported by rigid rings显示文摘 | Xavier Simon Sandrine Chazelet Dominique Thomas Denis Bémer Roland Régnier | 2006 | Powder Technology2006，，2： | 2 |
| 7 | Mobilization of CD34^+CD38^- hematopoietic stem cells after priming in acute myeloid leukemia显示文摘AIM: To evaluate quantitatively and qualitatively the different CD34+cell subsets after priming by chemotherapy granulocyte colony-stimulating factor(± G-CSF)in patients with acute myeloid leukemia.METHODS: Peripheral blood and bone marrow sampleswere harvested in 8 acute myeloid leukemia patients during and after induction chemotherapy. The CD34/CD38 cell profile was analyzed by multi-parameter flow cytometry. Adhesion profile was made using CXC chemokine receptor 4(CXCR4)(CD184), VLA-4(CD49d/CD29) and CD47.RESULTS: Chemotherapy ± G-CSF mobilized immature cells(CD34+CD38 population), while the more mature cells(CD34+CD38lowand CD34+CD38+populations) decreased progressively after treatment. Circulating CD34+cells tended to be more sensitive to chemotherapy after priming with G-CSF. CD34+cell mobilization was correlated with a gradual increase in CXCR4 and CD47expression, suggesting a role in cell protection and the capacity of homing back to the marrow.CONCLUSION: Chemotherapy ± G-CSF mobilizes into the circulation CD34+bone marrow cells, of which, the immature CD34+CD38-cell population. Further manipulations of these interactions may be a means with which to control the trafficking of leukemia stem cells to improve patients' outcomes. | Adriana Plesa Eve Mattei Charles Dumontet Youcef Chelghoum Hélène Labussière Giovanna Cannas Mauricette Michallet Xavier Thomas Mohamed Elhamri Stéphane Morisset Inès Tagoug | 2013 | World Journal of Stem Cells2013，5，4： | 1 |
| 8 | Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors显示文摘 | Daan Dierickx Thomas Tousseyn Xavier Sagaert Steffen Fieuws Iwona Wlodarska Julie Morscio Lieselot Brepoels Dirk Kuypers Johan Vanhaecke Frederik Nevens Geert Verleden Rita Van Damme-Lombaerts Marleen Renard Jacques Pirenne Christiane De Wolf-Peeters Greg | 2013 | Leukemia & Lymphoma2013，，11： | 1 |
| 9 | Treatment of philadelphia chromosome-positive adult acute lymphoblastic leukemia显示文摘 | Xavier Thomas Herve Dombret | 2008 | Leukemia and Lymphoma2008，49，7： | 1 |
| 10 | Rationale and design of a randomized controlled trial evaluating community health worker–based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD)显示文摘 | Deepak Y. Kamath Denis Xavier Rajeev Gupta P.J. Devereaux Alben Sigamani Tanvir Hussain Sowmya Umesh Freeda Xavier Preeti Girish Nisha George Tinku Thomas N. Chidambaram Rajnish Joshi Prem Pais Salim Yusuf | 2014 | American Heart Journal2014，，： | 1 |
| 11 | DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences显示文摘 | Xavier Thomas | 2012 | Expert Opinion on Drug Discovery2012，，11： | 1 |
| 12 | Image-Guided Robotic Stereotactic Body Radiation Therapy for Liver Metastases: Is There a Dose Response Relationship?显示文摘 | Claire Vautravers-Dewas Sylvain Dewas Fran?ois Bonodeau Antoine Adenis Thomas Lacornerie Nicolas Penel Eric Lartigau Xavier Mirabel | 2011 | International Journal of Radiation Oncology Biology Physics2011，，3： | 1 |
| 13 | Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis显示文摘 | Jason S Gold Mithat G?nen Antonio Gutiérrez Javier Martín Broto Xavier García-del-Muro Thomas C Smyrk Robert G Maki Samuel Singer Murray F Brennan Cristina R Antonescu John H Donohue Ronald P DeMatteo | 2009 | Lancet Oncology2009，，11： | 1 |
| 14 | Comprehensive Control of Human Papillomavirus Infections and Related Diseases显示文摘 | F. Xavier Bosch Thomas R. Broker David Forman Anna-Barbara Moscicki Maura L. Gillison John Doorbar Peter L. Stern Margaret Stanley Marc Arbyn Mario Poljak Jack Cuzick Philip E. Castle John T. Schiller Lauri E. Markowitz William A. Fisher Karen Canfell Lyn | 2013 | Vaccine2013，，： | 1 |
| 15 | Multicenter,Randomized,Open-Label,Phase III Trial of Decitabine Versus Patient Choice,With Physician Advice,of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia显示文摘 | Thomas Xavier G Dmoszynska Anna Wierzbowska A | 2012 | J Clin Oncol2012，30，21： | 1 |
| 16 | Consequences of high transitory airflows generated by segmented pulse-jet cleaning of dust collector filter bags显示文摘 | Xavier Simon Denis Bémer Sandrine Chazelet Dominique Thomas Roland Régnier | 2010 | Powder Technology2010，，1： | 1 |
| 17 | A cooperative workflow management system with the Meta-Object Facility显示文摘 | Le pallec Xavier Vantroys Thomas | 2001 | IEEE Software2001，，： | 1 |
| 18 | Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation显示文摘 | Thomas S Jean-Chares Xavier C | 2004 | Arthritis & Rheumatism2004，50，11： | 1 |
| 19 | High styrene-rubber lonomers,an alternative to ther moplastic elastomers显示文摘 | JACOB SAMUEL THOMMACHAN XAVIER THOMAS KU RIAN | 2002 | Journal of Applied Polymer Science2002，85，11： | 1 |
| 20 | Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis显示文摘 | Jason S Gold Mithat G?nen Antonio Gutiérrez Javier Martín Broto Xavier García-del-Muro Thomas C Smyrk Robert G Maki Samuel Singer Murray F Brennan Cristina R Antonescu John H Donohue Ronald P DeMatteo | 2009 | Lancet Oncology2009，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员